GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
Glucagon-like peptide-1 receptor agonists
Heart failure
Major adverse cardiovascular events
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
22 Jan 2024
22 Jan 2024
Historique:
received:
29
05
2023
accepted:
06
12
2023
medline:
22
1
2024
pubmed:
22
1
2024
entrez:
22
1
2024
Statut:
aheadofprint
Résumé
Glucagon-like peptide-1 receptor agonists (GLP1-ra) have shown to reduce cardiovascular (CV) events in patients with diabetes, including heart failure (HF) hospitalizations. However, whether such benefit consistently occurs in patients with history of HF remains uncertain. We performed a systematic review and meta-analysis to assess the impact of GLP1-ra on CV outcomes in patients with and without HF history. All randomized, placebo-controlled trials evaluating GLP1-ra and reporting CV outcomes stratified by HF history were searched in Pubmed from inception to November 12th, 2023. The primary outcome was HF hospitalizations. Secondary outcomes included CV death, the composite of CV death and hospitalizations for HF, and major adverse cardiovascular events (MACE). Hazard ratio (HR) and 95% confidence interval (CIs) were used as effect estimates and calculated with a random-effects model. 68,653 patients (GLP1-ra = 34,301, placebo = 34,352) from 10 trials were included. GLP1-ra reduced HF hospitalization (no HF: HR = 0.79, 95% CI 0.63-0.98; HF: HR = 1.00, 95% CI 0.82-1.24, p GLP1-ra do not decrease HF-hospitalization risk, despite a potential benefit in patients without history of HF, but are effective in reducing ischemic events irrespective of the presence of HF. PROSPERO-registered (CRD42022371264).
Identifiants
pubmed: 38252145
doi: 10.1007/s00392-023-02362-6
pii: 10.1007/s00392-023-02362-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002. https://doi.org/10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF
doi: 10.1056/NEJMOA2032183/SUPPL_FILE/NEJMOA2032183_DATA-SHARING.PDF
pubmed: 33567185
Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373(1):11–22. https://doi.org/10.1056/NEJMOA1411892/SUPPL_FILE/NEJMOA1411892_DISCLOSURES.PDF
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228–1239. https://doi.org/10.1056/NEJMOA1612917/SUPPL_FILE/NEJMOA1612917_DISCLOSURES.PDF
doi: 10.1056/NEJMOA1612917/SUPPL_FILE/NEJMOA1612917_DISCLOSURES.PDF
pubmed: 28910237
pmcid: 9792409
Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841–851. https://doi.org/10.1056/NEJMOA1901118/SUPPL_FILE/NEJMOA1901118_DATA-SHARING.PDF
doi: 10.1056/NEJMOA1901118/SUPPL_FILE/NEJMOA1901118_DATA-SHARING.PDF
pubmed: 31185157
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844. https://doi.org/10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF
doi: 10.1056/NEJMOA1607141/SUPPL_FILE/NEJMOA1607141_DISCLOSURES.PDF
pubmed: 27633186
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. Drug Ther Bull 54(9):101. https://doi.org/10.1056/NEJMOA1603827/SUPPL_FILE/NEJMOA1603827_DISCLOSURES.PDF
doi: 10.1056/NEJMOA1603827/SUPPL_FILE/NEJMOA1603827_DISCLOSURES.PDF
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121–130. https://doi.org/10.1016/S0140-6736(19)31149-3
doi: 10.1016/S0140-6736(19)31149-3
pubmed: 31189511
Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392(10157):1519–1529. https://doi.org/10.1016/S0140-6736(18)32261-X
doi: 10.1016/S0140-6736(18)32261-X
pubmed: 30291013
Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385(10):896–907. https://doi.org/10.1056/NEJMOA2108269/SUPPL_FILE/NEJMOA2108269_DATA-SHARING.PDF
doi: 10.1056/NEJMOA2108269/SUPPL_FILE/NEJMOA2108269_DATA-SHARING.PDF
pubmed: 34215025
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247–2257. https://doi.org/10.1056/NEJMOA1509225/SUPPL_FILE/NEJMOA1509225_DISCLOSURES.PDF
doi: 10.1056/NEJMOA1509225/SUPPL_FILE/NEJMOA1509225_DISCLOSURES.PDF
pubmed: 26630143
Lam CSP, Ramasundarahettige C, Branch KRH et al (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O Trial. Circulation 145(8):565–574. https://doi.org/10.1161/CIRCULATIONAHA.121.057934
doi: 10.1161/CIRCULATIONAHA.121.057934
pubmed: 34775781
Zelniker TA, Wiviott SD, Raz I et al (2019) Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139(17):2022–2031. https://doi.org/10.1161/CIRCULATIONAHA.118.038868
doi: 10.1161/CIRCULATIONAHA.118.038868
pubmed: 30786725
Association AD (2021) 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care 44(Supplement_1):S125–S150. https://doi.org/10.2337/DC21-S010
Giugliano D, Scappaticcio L, Longo M et al (2021) GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol 20(1):1–11. https://doi.org/10.1186/S12933-021-01366-8/FIGURES/10
doi: 10.1186/S12933-021-01366-8/FIGURES/10
Margulies KB, Hernandez AF, Redfield MM et al (2016) Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316(5):500–508. https://doi.org/10.1001/JAMA.2016.10260
doi: 10.1001/JAMA.2016.10260
pubmed: 27483064
pmcid: 5021525
Jorsal A, Kistorp C, Holmager P et al (2017) Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19(1):69–77. https://doi.org/10.1002/EJHF.657
doi: 10.1002/EJHF.657
pubmed: 27790809
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 6(7):e1000097. https://doi.org/10.1371/JOURNAL.PMED.1000097
doi: 10.1371/JOURNAL.PMED.1000097
pubmed: 19621072
pmcid: 2707599
Branch KRH, Dagenais GR, Avezum A et al (2022) Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. Eur J Heart Fail. https://doi.org/10.1002/EJHF.2670 . (Published online)
doi: 10.1002/EJHF.2670
pubmed: 36224326
Ferreira JP, Neves JS (2022) Glucagon-like peptide 1 receptor agonists in heart failure: the need for a rewind. Eur J Heart Fail 24(10):1813–1815. https://doi.org/10.1002/EJHF.2693
doi: 10.1002/EJHF.2693
pubmed: 36102183
Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326(7382):219. https://doi.org/10.1136/BMJ.326.7382.219
doi: 10.1136/BMJ.326.7382.219
pubmed: 12543843
pmcid: 1125071
Kosiborod MN, Abildstrøm SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. https://doi.org/10.1056/NEJMOA2306963/SUPPL_FILE/NEJMOA2306963_DATA-SHARING.PDF (Published online September 21, 2023)
Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. https://doi.org/10.1056/NEJMoa2307563 (Published online November 11, 2023)
Husain M, Bain SC, Jeppesen OK et al (2020) Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 22(3):442–451. https://doi.org/10.1111/DOM.13955
doi: 10.1111/DOM.13955
pubmed: 31903692
pmcid: 7064975
Dunlay SM, Givertz MM, Aguilar D et al (2019) Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation 140(7):E294–E324. https://doi.org/10.1161/CIR.0000000000000691
doi: 10.1161/CIR.0000000000000691
pubmed: 31167558
Dei Cas A, Khan SS, Butler J et al (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3(2):136–145. https://doi.org/10.1016/J.JCHF.2014.08.004
doi: 10.1016/J.JCHF.2014.08.004
pubmed: 25660838
Pop-Busui R, Januzzi JL, Bruemmer D et al (2022) Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care 45(7):1670–1690. https://doi.org/10.2337/DCI22-0014
doi: 10.2337/DCI22-0014
pubmed: 35796765
pmcid: 9726978
Echouffo-Tcheugui JB, Ndumele CE, Zhang S et al (2022) Diabetes and progression of heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Coll Cardiol 79(23):2285–2293. https://doi.org/10.1016/J.JACC.2022.03.378
doi: 10.1016/J.JACC.2022.03.378
pubmed: 35680178
pmcid: 10125541
Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM (2015) Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3(5):356–366. https://doi.org/10.1016/S2213-8587(15)00044-3
doi: 10.1016/S2213-8587(15)00044-3
pubmed: 25791290
Fei Y, Tsoi MF, Cheung BMY (2019) Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetol. https://doi.org/10.1186/S12933-019-0916-Z
doi: 10.1186/S12933-019-0916-Z
pubmed: 31462224
pmcid: 6714383
Cosentino F, Grant PJ, Aboyans V et al (2020) 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41(2):255–323. https://doi.org/10.1093/EURHEARTJ/EHZ486
doi: 10.1093/EURHEARTJ/EHZ486
pubmed: 31497854
Razuk V, Chiarito M, Cao D et al (2022) SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. Eur Hear J Cardiovasc Pharmacother 8(6):557–567. https://doi.org/10.1093/EHJCVP/PVAC001
doi: 10.1093/EHJCVP/PVAC001
Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):E895–E1032. https://doi.org/10.1161/CIR.0000000000001063
doi: 10.1161/CIR.0000000000001063
pubmed: 35363499
Adhikari R, Jha K, Dardari Z et al (2015) National trends in use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists by cardiologists and other specialties, 2015 to 2020. J Am Heart Assoc. https://doi.org/10.1161/JAHA.121.023811
doi: 10.1161/JAHA.121.023811
Nair R, Mody R, Yu M, Cowburn S, Konig M, Prewitt T (2022) Real-world treatment patterns of glucose-lowering agents among patients with type 2 diabetes mellitus and cardiovascular disease or at risk for cardiovascular disease: an observational, cross-sectional, retrospective study. Diabetes Ther 13(11–12):1921–1932. https://doi.org/10.1007/S13300-022-01320-1
doi: 10.1007/S13300-022-01320-1
pubmed: 36131064
pmcid: 9663782
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837. https://doi.org/10.1016/J.CMET.2013.04.008
doi: 10.1016/J.CMET.2013.04.008
pubmed: 23684623
Lee YS, Jun HS (2016) Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediat Inflamm. https://doi.org/10.1155/2016/3094642
doi: 10.1155/2016/3094642
Skov J, Dejgaard A, Frøkiær J et al (2013) Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98(4):E664–E671. https://doi.org/10.1210/JC.2012-3855
doi: 10.1210/JC.2012-3855
pubmed: 23463656
Meier JJ, Rosenstock J, Hincelin-Méry A et al (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label. Trial Diabetes Care 38(7):1263–1273. https://doi.org/10.2337/DC14-1984
doi: 10.2337/DC14-1984
pubmed: 25887358
Ibrahim NE, Gaggin HK, Turchin A et al (2019) Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. Eur Hear J Cardiovasc Pharmacother 5(1):3–11. https://doi.org/10.1093/EHJCVP/PVY011
doi: 10.1093/EHJCVP/PVY011
Adamson C, Kondo T, Jhund PS et al (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 43(41):4406–4417. https://doi.org/10.1093/EURHEARTJ/EHAC481
doi: 10.1093/EURHEARTJ/EHAC481
pubmed: 36029309
pmcid: 9622300
Ghosh-Swaby OR, Goodman SG, Leiter LA et al (2020) Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol 8(5):418–435. https://doi.org/10.1016/S2213-8587(20)30038-3
doi: 10.1016/S2213-8587(20)30038-3
pubmed: 32333878
Anker SD, Khan MS, Butler J et al (2022) Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. Eur J Heart Fail. https://doi.org/10.1002/EJHF.2728 . (Published online November 24)
doi: 10.1002/EJHF.2728
pubmed: 36325584
Rossignol P, Masson S, Barlera S et al (2015) Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail 17(4):424–433. https://doi.org/10.1002/EJHF.240
doi: 10.1002/EJHF.240
pubmed: 25704364
Vedin O, Lam CSP, Koh AS et al (2017) Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.117.003875/-/DC1
doi: 10.1161/CIRCHEARTFAILURE.117.003875/-/DC1
pubmed: 28615366
Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653–662. https://doi.org/10.1016/S2213-8587(21)00203-5
doi: 10.1016/S2213-8587(21)00203-5
pubmed: 34425083
Caruso I, Cignarelli A, Giorgino F (2019) Heterogeneity and similarities in GLP-1 receptor agonist cardiovascular outcomes trials. Trends Endocrinol Metab 30(9):578–589. https://doi.org/10.1016/j.tem.2019.07.004
doi: 10.1016/j.tem.2019.07.004
pubmed: 31401015
Dunlay SM, Redfield MM, Weston SA et al (2009) Hospitalizations after heart failure diagnosis: a community perspective. J Am Coll Cardiol 54(18):1695. https://doi.org/10.1016/J.JACC.2009.08.019
doi: 10.1016/J.JACC.2009.08.019
pubmed: 19850209
pmcid: 2803107
Ferreira JP, Saraiva F, Sharma A, et al. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab. https://doi.org/10.1111/DOM.14997 (Published online 2023)
Banerjee M, Maisnam I, Mukhopadhyay S (2023) Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis. Cardiovasc Drugs Ther 1:1–8. https://doi.org/10.1007/S10557-023-07432-5/FIGURES/2
doi: 10.1007/S10557-023-07432-5/FIGURES/2